Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other severe conditions driven by protein growth factors, has officially submitted a Biologics License Application (BLA) to the U.S.…
Sage Therapeutics Explores Strategic Alternatives and Rejects Biogen’s Acquisition Offer Sage Therapeutics, Inc. (Nasdaq: SAGE), a leader in brain health therapeutics, announced today that its Board of Directors has initiated a formal process to explore strategic alternatives for the company.…
Genentech Announces Positive OS Results for Itovebi in Advanced HR-Positive Breast Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced positive topline results from the Phase III INAVO120 study investigating the combination of Itovebi™…
Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com The global cannabis pharmaceuticals market, valued at USD 3.46 billion in 2023, is expected to experience remarkable growth, reaching USD 380.77 billion by 2034. This expansion is forecasted…
ENHERTU® Approved in U.S. for HER2-Low Metastatic Breast Cancer Post-Endocrine Therapy Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)…
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen—bortezomib, lenalidomide, and dexamethasone (VRd)—for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for…
UCB is A global biopharmaceutical leader committed to improving the lives of people living with severe diseases, highlighted its decade of growth and strategic priorities at the 43rd J.P. Morgan Healthcare Conference in San Francisco. For nearly a century, It…
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802 Pheno Therapeutics Limited, a leading biotechnology company focused on developing small molecule therapeutics for neurological diseases, has received Clinical Trial Authorisation (CTA) from the UK’s Medicines and Healthcare products Regulatory…
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses At the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG revealed significant advancements in its pharmaceutical growth strategy, announcing multiple filings for key drugs such as darolutamide, finerenone, acoramidis, and…
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma The National Medical Products Administration (NMPA) of China has granted approval for Sarclisa (isatuximab), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult…
Eli Lilly and Company has announced its preliminary revenue guidance for 2024 and 2025, showcasing significant growth and momentum in its operations. For 2024, Lilly anticipates full-year worldwide revenue to reach approximately $45.0 billion, representing an impressive 32% growth compared…
Eli Lilly and Company and Scorpion Therapeutics a private biotechnology company specializing in small molecule precision oncology therapies, have announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor program, STX-478. This cutting-edge compound is a once-daily oral, mutant-selective…